Board summary
Key figures
29,294
Registered population
56.7% aged 18–64
25.0%
Aged 65+
ICB 21.9% · England 17.9%
5.7%
Ethnic minority (non-White)
2.2% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,217
Hypertension register
+8.82% in 3 yrs · England +5.60%
311
SMI register
46.1% of Adur's
790
COPD register
Reviews -4.52% in 3 yrs
Forecast to 2030
7,467
Hypertension patients, 2030
+1,250 on today
83.8%
QRISK ≥20% on statins, 2030
+8.26pp over 3 yrs
6.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD and blood pressure reviews trail England.
COPD review coverage (75.6%) changed by -4.5% (England +2.8%) and hypertension control by -2.7% (England +3.6%), which may reflect recall pressure.
High lipid unit cost alongside statin gap.
Lipid-modifying items cost £4.50 (£123,821 more than at England's £1.86 unit cost across 46,902 items), while diabetes CVD statin coverage is 79.0% (England 84.4%).
Primary prevention lipid therapy and asthma gains.
QRISK ≥ 20% lipid therapy rose +15.0% to 63.4% (England +6.2%) and annual asthma reviews rose +9.8% (England +4.4%).
Population, age and ethnicity
Patients aged 65+ reach 25.0%, above England's 17.9% and Adur's 23.3%
Of 29,294 registered patients, 25.0% (7,321) are aged 65+ (Adur 23.3%, NHS Sussex Integrated Care Board 21.9%, England 17.9%). Working-age adults (18-64) represent 56.7% (Adur 58.0%, England 62.7%), and 18.3% are aged 0-17 (Adur 18.7%, England 19.6%). Projected list growth to 2030 (unverified methodology) is 1.0% (Adur 0.7%, England 2.3%). Census usual residents show a 94.3% White population (Adur 93.4%, England 81.1%), leaving a 5.7% ethnic minority share. An older demographic could concentrate chronic disease management and proactive frailty reviews across primary care.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Adur local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Adur LA) | 2,174 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Adur LA) | 1,147 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Adur LA) | 14.3 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Registered Core20 prevalence is 0.0% and average IMD decile is 5.9
The PCN records 0.0% of registered patients in Core20, matching Adur (0.0%) but below NHS Sussex Integrated Care Board (9.2%) and England (21.0%). Average IMD decile is 5.9 (Adur 6.6, NHS Sussex Integrated Care Board 6.1, England 5.5), and estimated Core20 residents total 0. With zero Core20 concentration, local inequality work could focus on clinical vulnerability, consistent with the PCN holding 60.4% of Adur's learning disability register (215 patients) and 46.1% of its severe mental illness register (311 patients).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
311
SMI register
1.07% recorded prevalence
215
Learning disability register
0.74% recorded prevalence
7
Care homes, 245 beds
In the PCN catchment
9.4%
Provide unpaid care
Adur, Census 2021
Recorded learning disability prevalence is 0.7% (215 patients; Adur 0.5%, NHS Sussex Integrated Care Board 0.6%, England 0.6%) and severe mental illness is 1.1% (311 patients; Adur 1.0%, England 1.0%). Catchment care homes contain 245 beds across 7 sites, although resident occupancy is unconfirmed. Higher recorded prevalence may increase primary care demand for annual health checks and care planning.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.1% (England 1.0%). Annual physical checks reached 80.3% for blood pressure (England 83.4%) and 79.8% for BMI (England 82.1%), falling to 74.8% and 75.7% at Ball Tree Surgery.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,217
Hypertension register
+8.82%
Register growth, 3 yrs
Adur +5.74% · England +5.60%
−1.25pp
BP control, under 80
≤140/90 · −0.03pp aged 80+
+1,250
More patients by 2030
Forecast 7,467 (25.30%)
Hypertension case-finding and control
Hypertension recorded prevalence is 21.4% (6,217 patients), exceeding Adur (19.2%), NHS Sussex Integrated Care Board (16.3%) and England (15.2%). Although recent blood pressure checks reach 91.6% (England 90.0%), treatment to threshold fell 2.7% between 2023 and 2025 to 69.9% (England +3.6%). In patients under 80, control fell 1.8% between 2023 and 2025 to 67.1% (England +3.2% to 67.8%), dropping to 58.6% at New Pond Row Surgery. This trend could reflect review or titration delays, which an audit of uncontrolled patients could test, particularly at New Pond Row Surgery.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy rose +15.0% between 2023 and 2025 (England +6.2%) to 63.4% (England 63.6%). However, secondary prevention statin treatment in diabetes with CVD is 79.0%, trailing England (84.4%). Prioritising medication reviews could address the secondary prevention gap.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 46,902 | £4.50 | £2.42 | £1.86 | £211,059 |
| Cardiovascular (all), 2025 | 59,219 | £4.25 | £3.32 | £3.33 | £251,681 |
In 2026, lipid-regulating prescribing cost £4.50 per item (England £1.86), spending £123,821 more than at England's unit cost across 46,902 items, alongside 6,406 items per 1,000 patients aged 65+ (England 18,056 rate). This cost indicator may reflect differing formulary mix, which a local prescribing review could test.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+9.81%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.56%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.7% (790 patients; England 1.9%), but reviews fell 4.5% between 2023 and 2025 (England +2.8%) to 75.6% (England 76.4%). Conversely, asthma reviews rose +9.8% between 2023 and 2025 (England +4.4%) to 63.0% (England 65.7%), leaving an unreviewed gap of about 860 patients across 2,329 registered. Childhood asthma prescribing reached 1,613 items per 1,000 aged 5–19 (England 1,488 rate). This pattern could reflect recall constraints, which a scheduling audit could test.
Cancer register and children's immunisation
Cancer recorded prevalence is 5.1% (1,478 patients; England 3.8%). In Q1 2025/26, 6-in-1 coverage reached 100.0% at 24 months, and MMR dose 1 reached 95.4% at age 5. However, age-5 booster coverage trailed the 95.0% target: MMR dose 2 was 93.8% (1.2 pp below target; a 1.6 pp drop from dose 1) and 4-in-1 booster was 90.8% (4.2 pp below target).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, across NHS Sussex ICB, 58.5% of cancers with a known stage (4,799 of 8,209) were diagnosed at stage 1 or 2, compared with 55.3% in England, remaining 16.5 pp below the 75.0% national ambition by 2028. Known stage was recorded for 64.3% of all registered cancers (8,209 of 12,766; England 67.0%), meaning unrecorded staging limits system comparisons. Locally, PCN breast screening coverage is 67.1% (England 69.9%, Adur 75.8%), while cervical screening in women aged 25–49 is 73.2% (England 66.8%), though coverage fell 2.4% over three years (England -1.0%). Lower screening uptake may delay early detection across local practices.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the cancer 62-day referral to treatment standard, trailing East Sussex Healthcare NHS Trust (67.0%), Surrey and Sussex Healthcare NHS Trust (70.0%), England (71.2%) and NHS Surrey and Sussex Integrated Care Board (71.5%), sitting 19.8 pp below the 85.0% standard. The trust reached 74.0% on the 28-day faster diagnosis standard (England 79.3%). For diagnostics, 12.9% waited 6+ weeks across all diagnostic tests (England 23.1%), though colonoscopy waits reached 39.3% (England 30.8%) and flexi sigmoidoscopy reached 45.4% (England 32.1%).
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 27.53 | 21.40 |
| CT | 8.57 | 0.48 | 18.49 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 43.78 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 15.11 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 21.06 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 28.50 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026, experimental community data recorded 115,485 care activities and 78,050 care contacts for West Sussex residents, alongside 316,320 activities and 309,615 contacts across NHS Surrey and Sussex Integrated Care Board. Adults aged 65+ accounted for 72.7% of West Sussex contacts (56,740 of 78,050). These provisional counts cover submitting providers only and describe local authority and system activity rather than unique PCN patients.
Practice variation and patient experience
Overall patient experience ranges from 47.2% to 83.4% across the three constituent practices
In 2025/26, all three practices attained 100.0% in QOF clinical-domain achievement (England 97.1%). Overall QOF achievement reached 96.7% at Ball Tree Surgery, 97.2% at New Pond Row Surgery, and 100.0% at The Orchard Surgery. Conversely, vaccination and immunisation achievement exhibited a 28.5 pp inter-practice range, varying from 71.5% at Ball Tree Surgery to 100.0% at The Orchard Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Ball Tree Surgery | 123 | 0.0 | 36.7% | 74.2% | 83.4% |
| Orchard | 110 | 0.0 | 42.4% | 86.3% | 70.9% |
| New Pond Row | 91 | 0.0 | 14.2% | 54.3% | 47.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 tracked measures trail England's three-year change, led by reviews
Fourteen of 25 tracked measures trail England's three-year change. Widest lags appear in routine chronic disease care: COPD reviews fell 4.5% over three years (England +2.8%, trailing by 7.27 points), hypertension treatment to target fell 2.7% (England +3.6%, trailing by 6.37 points), and heart failure reviews rose +4.2% (England +8.7%, trailing by 4.57 points). Smoking cessation offers also fell 4.7 pp (England +0.1 pp). Conversely, relative strengths include lipid therapy in QRISK ≥ 20% (+15.0% versus England +6.2%), asthma reviews (+9.8% versus +4.4%), and statins in diabetes without CVD (+4.5% versus +2.1%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Hypertension treated to target
BP control, under 80
Smoking support (SMI)
Alcohol record (psychosis)
QRISK statin treatment
Asthma reviews
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Adur | Asset | PCN | Adur |
|---|---|---|---|---|---|
| Care homes (catchment) | 7 (245 beds) | n/a | Schools (catchment) | 22 | n/a |
| Children's centres | 2 | 4 | Places of worship | 12 | 29 |
| Libraries | 1 | 3 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 1 | 1 | Carers support groups (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 1 | 5 | Primary academies | 2 | 7 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension control and recall audit
Across 6,217 patients (21.4% prevalence), hypertension treated to target (69.9%; England 70.3%) fell 2.7% (England +3.6%); control under 80 is 67.1% (New Pond Row Surgery 58.6%). For discussion, the PCN could run a structured recall and pharmacist-led titration review for patients above BP threshold, starting at New Pond Row Surgery. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Asthma and COPD review recall
Asthma review coverage is 63.0% (England 65.7%, Adur 60.1%) across 2,329 patients (about 860 unreviewed), while COPD reviews (75.6%; register 790) fell 4.5% (England +2.8%). For discussion, practices could standardise annual respiratory recall templates, offer flexible review slots, and check second-hand smoking recording (76.7% in ages 6-19 vs Adur 83.0%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
CVD statin and formulary review
Statin treatment in diabetes with CVD is 79.0% (England 84.4%), while lipid-modifying prescribing costs £4.50 per item (£123,821 more than at England's £1.86 unit cost across 46,902 items). Low cost, quick to run.
Evidence base: the stroke/TIA register is the cohort for AF anticoagulation and blood-pressure control (pre-stroke prevention) as well as hyperacute care; practices well below expected prevalence are the case-finding list, and the pre-stroke prevention gap concentrates in deprived practices.
Policy anchor: Core20PLUS5 (CVD); NHS CVD ambitions to 2029.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult care coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Clinical vulnerability outreach targeting (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness check outreach (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension control and recall audit (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Asthma and COPD review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · CVD statin and formulary review (p12) | Stroke register · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT · SSNAP | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
